India’s Dr. Reddy’s Aims For Rituximab, Peg-GCSF Biosimilars In U.S.
This article was originally published in PharmAsia News
Executive Summary
The Indian drug maker said it received approvals to conduct safety studies for two biosimilars and is working closely with the regulatory agencies. Analysts expect the trials may take roughly three years following which it will be ready for the product approvals in the U.S. market.